MDM2 and liposarcoma: The MDM2 inhibitor brigimadlin remains under clinical evaluation and has shown objective responses for patients with MDM2-amplified well-differentiated liposarcoma as well as prolonged stable disease for patients with dedifferentiated liposarcoma (LoRusso et al., 2023).